Eli Lilly releases discounted single-dose vials of Zepbound weight loss drug

Eli Lilly has announced a new, more affordable form of its obesity drug, aiming to make it accessible to more patients, especially those without insurance. The drug will be available in single-dose vials at a reduced cost, potentially impacting the market for other similar medications. This move comes amid scrutiny over high drug prices and aims to cater to patients whose insurance does not cover such medications. The CEO of Novo Nordisk highlighted the high cost of treating obesity, which burdens the healthcare system. A Senate committee hearing is scheduled to discuss these pricing issues.

What impact might Eli Lilly's new drug have on the market for other obesity medications?

What challenges do patients face regarding the cost of obesity treatment?